

12th World Congress on Alzheimers Disease & Dementia January 23-24, 2020 | Bangkok, Thailand


Nasreen Sultana

Professor at National Institute of Nuclear Medicine and Allied Sciences, Atomic Energy Commission, Bangladesh, E-mail: nasreeninm@yahoo.com

Dementia, including Alzheimer's disease, is one of the best overall general prosperity challenges facing our period. Around the globe, no under 44 million people are living with dementia this number is depended upon to two overlaps by 2030 and more than triple by 2050 to 115 million. A critical piece of the development will be in making countries like Western Europe and North America. Authoritatively 62% of people with dementia live in making countries. Today, more than 35 million people general directly live with the condition. This number is depended upon to twofold by 2030 and more than triple by 2050 to 115 million. No drugs available to direct or stop the cerebrum hurt caused by Alzheimer's disease, a couple of pharmaceuticals can quickly help upgrade the symptoms of dementia for a couple of individuals. In two decades, it is assessed that 1.4 million Canadians will have dementia, costing the economy almost \$300 billion consistently. Comprehensive, dementia cost \$600 billion a year.

Alzheimer's Disease and Therapeutic Market

Global Data estimated sales of AD therapeutics in 2016 to have been around \$3 billion over the seven major markets (7MM), which are the US, the five major European markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. By 2026, Global Data foresees the AD market will have developed at a solid Compound Annual Growth Rate (CAGR) of 17.5%, arriving at sales of \$14.8 billion over the 7MM. This is mostly credited to the developing pervasiveness of both AD and mild cognitive impairment (MCI) and the quick take-up of biologics and other novel disease therapies (DMTs).



Importance & Scope

Dementia is a general term that depicts a social affair of reactions, for instance, loss of memory, judgment, tongue, complex motor capacities, and other insightful limit caused by the enduring mischief or going of the cerebrum's nerve cells, or neurons. Dementia, including Alzheimer's disease, is one of the best overall general prosperity challenges standing up to our period.

All around, eventual outcomes of a current meta-examination prescribe that 44 million people lived with dementia worldwide in 2010, with numbers foreseen that would twofold at standard interims, to 65.7 million of each 2030 and 115.4 million out of 2050. In 2010, 58 percent shockingly with dementia lived in countries with low or focus compensation, with this degree predicted to rise to 63 percent in 2030 and 71 percent in 2050. This number is depended upon to twofold by 2030 and more than triple by 2050 to 115 million.

In the United States alone, experts gage that upwards of five million people age 65 and more settled experience the evil impacts of Alzheimer's affliction The AD advertise has an absence of helpful alternatives. Which classes of medication overwhelm the market?

Target Audience:

- Neurologists and Directors
- Physicians
- Neuroscientists
- Specialists
- Researchers
- Healthcare professionals
- Professors
- Industrial Experts
- Neurosurgeons
- Psychiatrist
- Nutritional Scientists
- Lecturers and Students from Academia in the study of Dementia
- Students from Academia in the research of Neurology

Related Companies/Industries:

- Roche. Listed Company
- AstraZeneca. Listed Company
- Genentech. Listed Company
- Memrise. Private Company
- Halo Neuroscience Private Company
- SAGE Therapeutics Listed Company
- Allergan. Listed Company

- Via .Private Company
- Allergan
- Eisai Co. Ltd
- Novartis AG
- Daiichi Sankyo Company Limited
- Merz Pharma
- Pfizer Inc
- Johnson & Johnson Services
- Lundbeck A/S

Related Associations and Societies:

- American Brain Foundation
- Fisher Center for Alzheimer's Research Foundation
- Alzheimer's Foundation of America
- Alzheimer's Research & Prevention Foundation
- Lewy Body Dementia Association,
- Alzheimer's Family Services Center
- Long Island Alzheimer's Foundation
- Alzheimer's Association - Dementia information and local support groups
- Alzheimer's Disease International
- Alzheimer's Europe - A good overview of the different types of Dementia
- Alzheimer's Foundation of America, Caregiver tips
- The Association for Frontotemporal Degeneration Young Dementia
- Alternating Hemiplegia of Childhood Foundation
- Alzheimer's Drug Discovery Foundation Neuropathy Association and Nevus Outreach
- National Parkinson Foundation

- Brain Tumor Research and Information
- Cure Alzheimer's Fund

Contact:

Program Manager | Alzheimers Disease & Dementia

mail: neuro@expert-meetings.com

Phone no: +1-201-380-5561

WhatsApp No: +44-203-7690-972